Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.INO Therapeutics and Forest Laboratories have entered into an agreement to co- promote Infasurf, a product indicated for the prevention and treatment of respiratory distress syndrome in high-risk premature infants.
Subscribe to our email newsletter
Infasurf (calfactant) intratracheal suspension decreases the incidence of respiratory distress syndrome (RDS), mortality due to RDS, and air leaks associated with RDS.
“We are pleased to add Infasurf to the product offering we bring to neonatologists and their patients in the neonatology intensive care units,” said INO Therapeutics’ president and CEO, Dennis Smith.
“With INOmax and Infasurf leading our product line, this is just the beginning of pursuing our company vision. We will continue to seek and secure additional products and services for the neonatal and critical care treatment areas,” he added.
INO Therapeutics is a global pharmaceutical company committed to critical care with a focus in the areas of heart and lung function. The company obtained FDA approval for INOmax (nitric oxide) for inhalation in 1999, creating the first and only FDA-approved drug product form of nitric oxide for inhalation.